Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2005
10/26/2005EP1589033A1 Antibody and use thereof
10/26/2005EP1589031A2 Production of polyketides and other natural products
10/26/2005EP1589028A2 Modified oligonucleotides, their preparation and their use
10/26/2005EP1589017A2 12,13-modified epothilone derivatives
10/26/2005EP1589013A2 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations
10/26/2005EP1589006A1 Oxa- and thiazole derivatives useful as antidiabetics and antidiobesity agents
10/26/2005EP1588715A1 Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same
10/26/2005EP1588714A2 Adjuvant systems and vaccines
10/26/2005EP1588713A1 Production of human papillomavirus HBV-11 capsid protein L1 and virus-like particles
10/26/2005EP1588712A1 Modulators of regulatory proteins
10/26/2005EP1588706A2 Use of AT1 receptor antagonists or AT2 receptor modulator for the treatment of conditions or diseases associated with the increase of AT1 or AT2 receptors.
10/26/2005EP1587838A2 Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
10/26/2005EP1587836A2 Cancerous disease modifying antibodies
10/26/2005EP1587810A1 Novel substituted 1,4]benzodioxino 2,3-e]isoindole derivatives, method for preparing same and pharmaceutical compositions containing same
10/26/2005EP1587550A2 Methods and compositions for administering therapeutic and diagnostic agents
10/26/2005EP1587536A1 Agents for the diagnosis and treatment of tumours that expose altered proteins on the cell surface
10/26/2005EP1587532A2 Survivin-derived peptides and use thereof
10/26/2005EP1587519A2 Treatment of cancer with 2-deoxyglucose
10/26/2005EP1587518A2 Antineoplastic ether lipid compounds with modifications at the sn-3 carbon
10/26/2005EP1587512A2 Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
10/26/2005EP1587480A2 Polyhydroxylated pyrrolizidine
10/26/2005EP1587476A2 Novel compositions and methods in cancer
10/26/2005EP1587474A2 Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses
10/26/2005EP1587405A2 Novel compositions and methods for cancer
10/26/2005EP1444264A4 Methods and materials for targeting and affecting selected cells
10/26/2005EP1441683A4 Trisubstituted triazine compounds, and methods for making an using the compounds, which have antitubulin activity
10/26/2005EP1430056B1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
10/26/2005EP1397354B1 Imidazole-2-carboxamide derivatives as raf kinase inhibitors
10/26/2005EP1390368B1 Disubstituted 7,9-guaninium halides as telomerase inhibitors
10/26/2005EP1368001B1 Pharmaceutical formulation comprising bicalutamide
10/26/2005EP1328236A4 Methods of decreasing or preventing pain using spicamycin derivatives
10/26/2005EP1299406B1 Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same
10/26/2005EP1185277B1 Use of FXR synthetic ligands for the treatment of diseseas linked to cholesterol imbalance and colon cancer
10/26/2005EP1169059B1 Docetaxel in combination with rhumab her2 for the treatment of cancers
10/26/2005EP1159455B1 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE
10/26/2005EP1151010B1 Human polyclonal antibodies from transgenic nonhuman animals
10/26/2005EP1137426B1 Breast cancer treatment using natural plant essential oils
10/26/2005EP0973727B1 Activated iododerivatives for the treatment of cancer and aids
10/26/2005CN1688714A Diagnosis and treatment of the tuberous sclerosis pathway
10/26/2005CN1688692A Cell proliferation inhibitors containing anti-glypican 3 antibody
10/26/2005CN1688605A Novel immunogenic lipopeptides comprising T-helper and cytotoxic T lymphocyte (CTL) epitopes
10/26/2005CN1688585A Antitumoral analogs of lamellarins
10/26/2005CN1688578A Phosphodiesterase 4 inhibitors
10/26/2005CN1688577A Triazaspiro [5.5] undecane derivatives and drugs comprising the same as the active ingredient
10/26/2005CN1688576A Thiophene compounds
10/26/2005CN1688572A Piperidinyl targeting compounds that selectively bind integrins
10/26/2005CN1688553A Chemical process
10/26/2005CN1688550A 2, 5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12
10/26/2005CN1688549A Compound having TGF-beta inhibitory activity and medicinal composition containing the same
10/26/2005CN1688548A Process for preparing quinolin antibiotic intermediates
10/26/2005CN1688547A A-'7-halo-2-quino (xa-) linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
10/26/2005CN1688532A Composition based on substituted 1, 3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
10/26/2005CN1688527A Fused benzene derivative and use
10/26/2005CN1688365A Therapeutic use
10/26/2005CN1688364A Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
10/26/2005CN1688326A 抗老化剂 Anti-aging agent
10/26/2005CN1688303A Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
10/26/2005CN1688302A Use of hydroxyoleic acid and similar compounds in the production of medicaments
10/26/2005CN1224712C Vector
10/26/2005CN1224707C Intracellular isoform of the interleukin-1 receptor antagonist
10/26/2005CN1224699C Preparation method for tumour cell comprising interleukin-23 gene and its use
10/26/2005CN1224630C Targetted polypeptide for specificity of liver cancer blood vessel
10/26/2005CN1224628C Preparation of solanine sulfurate and its use in medicine
10/26/2005CN1224623C 1-phenysulfonyl-1, 3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use
10/26/2005CN1224614C Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
10/26/2005CN1224423C Pharmaceutical composition improved in peroral absorbability
10/26/2005CN1224405C Medicine for preventing and treating cancer and its preparing process
10/26/2005CN1224403C Lung cancer treating medicine
10/26/2005CN1224395C Medical function of sophorine
10/26/2005CN1224392C Use of diosgenin for preparing medicine for anti-carcinoma of stomach
10/26/2005CN1224388C Modified prodrug forms of ap/amp
10/26/2005CN1224386C Fumagucin injection against cancers and its preparing method
10/26/2005CN1224385C Medicament contg. platinum complex compounds and use thereof
10/26/2005CN1224384C Dysuria remedies
10/25/2005US6958411 Antitumor agent; viricide
10/25/2005US6958389 Preparing a tetraphenylporphyrin derivative (V) comprising demetalizing a tetraphenylporphyrin derivative of the formula (IV) to obtain a tetraphenylporphyrin derivative represented by the formula (V):
10/25/2005US6958387 Human serpin polypeptides
10/25/2005US6958386 MUM-1 protein expressed by multiple myeloma-related gene
10/25/2005US6958357 Central nervous system disorders; antiallergens; respiratory system disorders
10/25/2005US6958354 Pyrazole compounds as transforming growth factor (TGF) inhibitors
10/25/2005US6958348 Side effect reduction
10/25/2005US6958344 Pyrimidine compounds and their use as modulators of chemokine receptor activity
10/25/2005US6958343 Treating psoriasis, a disease in which angiogenesis is associated with raised CXCR2 chemokine levels, or COPD.
10/25/2005US6958340 such as N-[3-methyl-5-(trifluoromethyl)phenyl]-4-(2-phenyl-1H-imidazol-1-yl)pyrimidin-2-amine; treating breast cancer; use in combination with estrogen receptor modulators such as tamoxifen and raloxifene
10/25/2005US6958336 Anticancer agents; immunosuppressants; antiallergens; antiinflammatory agents
10/25/2005US6958335 Use of imatinib, 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyridin-3-y l) pyrimidin-2-ylamino)phenyl)-benzamide or a pharmaceutically acceptable salt
10/25/2005US6958333 N'-(isoindolino[3,2-b]perhydro-1,3-oxazin-5-on-9-yl)-N-(pyridin-2-yl) urea, for example; cyclin-dependent kinase inhibitors; colon cancer treatment
10/25/2005US6958331 sulfonyl amine derivatives such as {2-(2,2-diphenyl-ethylamino)-5-[4-(4-isopropyl-piperazine-1-carbonyl)-piperidine-1-sulfonyl]-phenyl}-morpholin-4-yl-methanone; pain, inflammation, septic shock
10/25/2005US6958319 Stability and longer shelf life; bortezomib N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid
10/25/2005US6958241 Liposomes with outer surfaces having an affinity moiety that binds to a biological therapy target surface, and a hydrophilic polymer coating reversibly conjugated to said moiety; e.g. polymyxin B conjugate liposome for septic shock
10/25/2005US6958238 Isolated dishevelled associated kinases, polynucleotides encoding the kinases, and methods of use thereof
10/25/2005CA2331053C Compositions and methods for treating conditions responsive to estrogen
10/25/2005CA2284879C Ethylene glycol esters of monohydrobenzoporphyrin derivatives as photoactive agents
10/25/2005CA2251232C Method for gene transfer to the central nervous system
10/25/2005CA2185470C Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes
10/25/2005CA2120782C Thioxanthenone antitumor agents
10/20/2005WO2005097995A1 CANCER THERAPY VIA THE INHIBITION OF Skp-2 EXPRESSION
10/20/2005WO2005097988A1 Bone marrow-relevant cell participating the maintenance and/or repair of tissue
10/20/2005WO2005097813A1 Demethyl-cantharidin platinum complex isomers and their use
10/20/2005WO2005097803A1 Novel water-soluble prodrug
1 ... 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 ... 2211